News
GHRS
12.76
-0.55%
-0.07
GH Research to Participate in Neuro Perspectives Conference
TipRanks · 2d ago
Weekly Report: what happened at GHRS last week (0602-0606)?
Weekly Report · 6d ago
Psychedelic: atai, Beckly Psytech to combine in all-share transaction
TipRanks · 06/05 15:35
GH Research assumed with an Overweight at Cantor Fitzgerald
TipRanks · 06/04 12:20
Weekly Report: what happened at GHRS last week (0526-0530)?
Weekly Report · 06/02 10:22
GH Research to Present at ASCP Meeting on Breakthrough Depression Treatment
TipRanks · 05/27 11:28
Weekly Report: what happened at GHRS last week (0519-0523)?
Weekly Report · 05/26 10:21
GH Research to Present at ASCP Meeting on Depression Treatments
TipRanks · 05/21 11:28
Psychedelic stocks rise as FDA chief’s comments seen favorable to industry
Seeking Alpha · 05/20 14:46
Weekly Report: what happened at GHRS last week (0512-0516)?
Weekly Report · 05/19 10:16
GH Research Showcases Promising Depression Treatment Data at ASCP Meeting
TipRanks · 05/15 11:31
GH Research announces acceptance of presentation at ASCP
TipRanks · 05/15 11:22
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and GH Research (GHRS)
TipRanks · 05/13 01:51
Weekly Report: what happened at GHRS last week (0505-0509)?
Weekly Report · 05/12 10:17
GH Research: Promising Clinical Results and Strong Financial Position Justify Buy Rating
TipRanks · 05/09 19:25
GH Research Is Maintained at Buy by Guggenheim
Dow Jones · 05/09 16:48
GH Research Price Target Cut to $29.00/Share From $32.00 by Guggenheim
Dow Jones · 05/09 16:48
Guggenheim Maintains Buy on GH Research, Lowers Price Target to $29
Benzinga · 05/09 16:37
GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 05/09 13:44
HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target
Benzinga · 05/09 13:34
More
Webull provides a variety of real-time GHRS stock news. You can receive the latest news about Gh Research Plc through multiple platforms. This information may help you make smarter investment decisions.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.